Atypical Teratoid Rhabdoid Tumors (ATRT) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The primary tumor of the central nervous system (CNS) is known as atypical teratoid rhabdoid tumors (ATRT). In other words, it originates in the brain or spinal cord. Primary CNS tumors are categorized according to the patient's age, the location of the tumor, the type of tumor, how far it has spread, and any residual tumor after surgery. Less than 10% of children with brain tumors have ATRT, which is extremely rare. Although it can affect older kids and adults, the disorder is most prevalent in children under the age of three. An aggressive, unusual central nervous system tumor is called an atypical teratoma. A shorter overall median survival was observed in all retrospective series. Few prospective clinical trials have offered recommendations for the treatment of this aggressive tumor due to the disease's rarity, so no precise treatment guidelines have yet been established.

Description

The central nervous system (CNS) tumor Atypical Teratoid Rhabdoid Tumors (ATRT) is a primary tumor. Accordingly, the brain or spinal cord is where it begins. Primary CNS tumors are categorized according to the patient's age, the location of the tumor, the type of tumor, the extent of the tumour's spread, and any residual tumor after surgery. Grade IV tumors were the classification for all ATRTs. This indicates that it is cancerous and growing quickly. ATRTs frequently have a massive appearance, with fluid-filled regions emitting a striking glow. The SMARCB1 gene, also known as INI1, is altered in the majority of ATRT cases. Normally, this gene tells proteins to halt the growth of tumors. However, SMARCB1 is dysfunctional in ATRT and does not control tumor growth. The gene that produces a protein that regulates tumor growth malfunctions in ATRT. This genetic flaw is the cause of more than 90% of ATRT cases. Although this genetic defect most frequently manifests in cancer, it can also be inherited, so the doctor may suggest genetic testing. A person may occasionally have SMARCB1 in their DNA, which indicates that they were born with the gene. A variety of brand-new cells known as embryonic cells serve as the precursors for ATRT. These comprise mesenchymal cells, neuroepithelial cells, epithelial cells, and striated muscle cells. ATRT multiplies quickly and typically spreads to other regions of the central nervous system via the cerebrospinal fluid (CSF).

Atypical Teratoid Rhabdoid Tumors (ATRT) (Epidemiology)

Less than 10% of children with brain tumors experience ATRT, which is extremely rare. While older children and adults can also develop the disorder, children under the age of three are most susceptible. The Austrian Brain Tumor Registry conducted a nationwide survey of high-grade CNS malignancies (WHO grades III/IV) diagnosed in children (birth to 14 years) between 1996 and 2006, and 311 new CNS malignancies were discovered. The age-standardized incidence of atypical teratoma/chordate was 1.38 per million children, making it the sixth most frequent occurrence (6.1%). Primitive neuroectodermal tumors of the central nervous system and medulloblastoma are both relatively common in the age range from birth to two years, where incidence is highest. In total, initial diagnoses of atypical teratomas/chlamydial tumors were made in 47.4% of cases, and retrospective diagnoses were made in 52.6% of cases. Atypical teratoma/chordates had a 5-year survival rate of 39.5%, 66.7% when they were properly diagnosed, and 15.0% when they weren't (P = 0.0469). Similar to this, 43 atypical teratoma patients who received treatment at the King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia between 1996 and 2013 were examined there. The median overall survival was 16.9 months (95% confidence interval: 5.2-32.9 months), and the estimated 2-year and 5-year overall survival rates were 41.9 9.6% and 27.9 9.2%, respectively. Patients who underwent triple therapy, which included surgery, chemotherapy, and radiation therapy, had a significantly higher overall median survival than peers (P value and lt; 0.001). Atypical teratogenic rhabdoid tumor (ATRT) affects 60 to 75 patients in the US each year, with a 5-year survival rate of about 30%.

Atypical Teratoid Rhabdoid Tumors (ATRT) -Current Market Size & Forecast Trends

The market for atypical teratoid rhabdoid tumors (ATRT) is expected to grow steadily, with projections indicating a value of approximately USD 250.1 million by 2030, growing at a compound annual growth rate (CAGR) of 5.1% from recent years. ATRT primarily affects infants and young children, making early diagnosis and treatment critical. The market growth is also supported by the development of targeted therapies and clinical trials aimed at improving patient outcomes. Overall, the ATRT market is positioned for gradual growth through 2035 as new treatment strategies and innovations continue to emerge.

An aggressive and uncommon tumor of the central nervous system is called an atypical teratoma. There was a shorter median overall survival in every retrospective series. There are currently no established clear treatment guidelines for this aggressive tumor due to the rarity of the disease and the paucity of prospective clinical trials that have offered recommendations. Surgery should be used as the first line of defense against ATRT. Surgery aims to remove as much of the tumor as possible without causing the patient any additional symptoms while also obtaining tissue to identify the type of tumor. Following surgery, patients with ATRT frequently receive further care, such as radiation therapy, chemotherapy, or clinical trials. There may also be clinical trials for drugs used in targeted therapy, immunotherapy, or neoadjuvant chemotherapy, all of which could be used as a potential treatment. The patient's medical team will choose a course of treatment based on the patient's age, tumor type, location, and residual tumor following surgery.

Report Highlights

Atypical Teratoid Rhabdoid Tumors (ATRT) - Current Market Trends

Atypical Teratoid Rhabdoid Tumors (ATRT) - Current & Forecasted Cases across the G8 Countries

Atypical Teratoid Rhabdoid Tumors (ATRT) - Market Opportunities and Sales Potential for Agents

Atypical Teratoid Rhabdoid Tumors (ATRT) - Patient-based Market Forecast to 2035

Atypical Teratoid Rhabdoid Tumors (ATRT) - Untapped Business Opportunities

Atypical Teratoid Rhabdoid Tumors (ATRT) - Product Positioning Vis-a-vis Competitors' Products

Atypical Teratoid Rhabdoid Tumors (ATRT) - KOLs Insight